CLINICAL TRIALS PROFILE FOR CINRYZE
✉ Email this page to a colleague
All Clinical Trials for CINRYZE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01151735 ↗ | C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation | Withdrawn | Penn State University | Phase 4 | 2010-07-01 | The study hypothesis is that treatment of Hereditary Angioedema at the time of prodromal symptoms will decrease morbidity associated with the disease |
| NCT01759602 ↗ | C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation | Completed | ViroPharma | Phase 1 | 2013-01-01 | The overall objective is to evaluate the tolerability/safety and preliminary efficacy of CINRYZE® (C1 esterase inhibitor [human]) as add-on therapy for treatment of acute optic neuritis and/or transverse myelitis in NMO and NMOSD. Primary Objective: To evaluate the safety and tolerability of 3-5 doses of 1000 - 2000 Units intravenous CINRYZE in NMO/NMOSD patients during an acute exacerbation. Secondary Objectives: - To determine the frequency of adverse events with CINRYZE in this patient population. - To determine the effect of CINRYZE on NMO clinical scores (Expanded Disability Status Scale and Low Contrast Visual Acuity). - To compare the change in MRI lesion size and extent following a course of CINRYZE. |
| NCT01759602 ↗ | C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation | Completed | Michael Levy | Phase 1 | 2013-01-01 | The overall objective is to evaluate the tolerability/safety and preliminary efficacy of CINRYZE® (C1 esterase inhibitor [human]) as add-on therapy for treatment of acute optic neuritis and/or transverse myelitis in NMO and NMOSD. Primary Objective: To evaluate the safety and tolerability of 3-5 doses of 1000 - 2000 Units intravenous CINRYZE in NMO/NMOSD patients during an acute exacerbation. Secondary Objectives: - To determine the frequency of adverse events with CINRYZE in this patient population. - To determine the effect of CINRYZE on NMO clinical scores (Expanded Disability Status Scale and Low Contrast Visual Acuity). - To compare the change in MRI lesion size and extent following a course of CINRYZE. |
| NCT02435732 ↗ | CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60% | Not yet recruiting | Shire | Phase 1 | 2020-12-01 | Limiting brain death-induced organ injury through a systemic anti- inflammatory medical management should allow for improvement in the quality of transplanted organs, and as a result, clinical improvement in post-transplant outcomes represented by a decrease in the incidence of delayed graft function (DGF) after transplantation. The specific aim is to evaluate the effect of C1INH (CINRYZE) as a donor pre-treatment strategy to decrease systemic inflammation and decrease the incidence of DGF in Expanded Criteria Donors (ECD), currently identified as donors with Kidney Donor Profile Index (KDPI) greater than or equal to 60%. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CINRYZE
Condition Name
Clinical Trial Locations for CINRYZE
Trials by Country
Clinical Trial Progress for CINRYZE
Clinical Trial Phase
Clinical Trial Sponsors for CINRYZE
Sponsor Name
